Response to treatment in acute non-lymphatic leukaemia: prognostic value of colony forming and colony stimulating capacities of bone marrow and blood cells compared to other parameters

British Journal of Haematology
M BeranA M Udén

Abstract

Growth of bone marrow and mononuclear white blood cells (MWBC) in soft-agar cultures was studied in 26 patients with untreated acute non-lymphocytic leukaemia (ANLL). Marrow and MWBC from 30 healthy volunteers served as controls. All ANLL patients revealed an abnormal growth in vitro. Patients with an increased number of clones in marrow cultures and large cluster predominance ('excessive growth') responded poorly to therapy with only one of 10 patients entering remission. On the contrary, only two of the 15 patients with a decreased clone number ('low growth') failed to achieve remission. The number of colonies and clusters in both bone marrow and blood cultures was significantly lower at presentation in patients who later entered remission than in those who did not. The correlations between the number of colonies and clusters in the blood and the marrow cultures were statistically significant. No significant correlations were found between prognosis or colony formation, on one hand, and the production of colony stimulating activity (CS)bA), by bone marrow and blood cells of ANLL patients, on the other. Nor could such correlations be found between prognosis, blood cell counts, and age. It is concluded that the growth pattero c...Continue Reading

References

May 1, 1977·Scandinavian Journal of Haematology·S Knudtzon
Aug 1, 1975·Cancer·B D ClarksonJ H Burchenal
Mar 1, 1972·Annals of Internal Medicine·J A LeviF W Gunz
Jan 1, 1974·Annals of Internal Medicine·V GrannB Clarkson
Sep 1, 1974·Acta Medica Scandinavica·M Granström, G Gahrton
May 1, 1969·Archives of Internal Medicine·D R BoggsG E Cartwright
Jun 3, 1971·The New England Journal of Medicine·P L GreenbergS L Schrier
Aug 1, 1970·Journal of Cellular Physiology·B L Pike, W A Robinson

❮ Previous
Next ❯

Citations

Jan 1, 1987·Journal of Tongji Medical University = Tong Ji Yi Ke Da Xue Xue Bao·C Y LiG X Sun
Oct 11, 1980·British Medical Journal·J A Whittaker
Apr 1, 1995·Leukemia & Lymphoma·P E HollingsP H Fitzgerald
Feb 1, 1986·European Journal of Cancer & Clinical Oncology·H H Gerhartz, W Wilmanns
Apr 1, 1982·The American Journal of Medicine·J J KirshnerA J Gottlieb
Jan 1, 1986·Critical Reviews in Clinical Laboratory Sciences·R W Trewyn, M R Grever
Feb 1, 1983·American Journal of Hematology·C M Richman, J D Rowley
Jan 1, 1988·Immunopharmacology and Immunotoxicology·G VasilopoulosP Cazzola
Nov 1, 1980·Scandinavian Journal of Haematology·P L Greenberg
May 1, 1981·Scandinavian Journal of Haematology·A GustavssonH Sigurdardottir
Apr 1, 1984·Scandinavian Journal of Haematology·A GustavssonI Olsson
Jan 1, 1984·Critical Reviews in Oncology/hematology·H E Broxmeyer
Jan 1, 1988·Critical Reviews in Oncology/hematology·H E Broxmeyer, D E Williams
Jan 1, 1984·Medical Oncology and Tumor Pharmacotherapy·J MinowadaP Reizenstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.